The Use of Avaulta for Anterior Repair
Recruitment status was: Recruiting
Vaginal prolapse is a well-known disease and is observed in approximately 11% of all postmenopausal women and tending to increase with age. Consequently, many surgical procedures have been developed in order to ensure sufficient support for the bladder, rectum or vaginal vault depending on the site of the defect. However, many procedures are associated with a high recurrence rate up to 40 % even within one to two years after the surgical procedure.
Due to the high recurrence rate new methods include the use of mesh, either biologically or synthetic. The latter is a permanent implant and therefore theoretically may result in a long-lasting anatomically correct position of the prolapse.
Although the recurrence rate may be lower using a mesh such surgical procedures may be associated with adverse events such as erosions of the vaginal mucosa. Others have observed shrinkage of the vaginal mucosa. However, in these studies large prolene mesh have been used. In contrast the recurrence rate is lowered up to 25%.
The above-mentioned advantage of synthetic mesh is however, mostly based on few non-randomised studies. The investigators therefore find it of importance to evaluate whether a surgical procedure using a mesh implant is superior to conventional surgical techniques. The present study is a clinical controlled study where patients with anterior vaginal prolapse are randomised to either a mesh technique or a standard anterior procedure.
The present study includes only two more visits at the outpatient clinic after the surgical procedure. Furthermore the patients have to fulfil questionnaires regarding urinary and faecal leakage and sexual habits.
Any participation in the study is totally voluntary and the patient may at any time withdraw herself. In any case the patient will receive the investigators' standard treatment.
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
|Official Title:||The Use of Avaulta for Anterior Repair. A Multicenter Randomised Prospective Controlled Study|
- Does Avaulta reduce the recurrence rate [ Time Frame: 0ct 2008 - July 2010 ]
- Does Avaulta improve prolapse symptoms, quality of life and sexual function [ Time Frame: oct 2008-July 2010 ]
|Study Start Date:||October 2008|
|Estimated Study Completion Date:||July 2010|
|Estimated Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
Active Comparator: Avaulta mesh
Procedure: Avaulta mesh
Insertion of a mesh vs conventional repair
Active Comparator: Anterior repair
Procedure: Anterior repair
The use of Avaulta for anterior repair. A multicenter randomised prospective controlled study.
During the resent years the methods for pelvic organ prolapse repair have changed rapidly. The reason for this is several. Firstly, there is a relative high recurrence rate in patients having an anterior vaginal repair. Thus, the rate has been estimated to be close to 40% or even higher and most often the recurrences occurs within the first two years. Weber et al and Sand et al reported various techniques of the anterior colporrhaphy without the use of mesh to be successful in the management of cystoceles in only 42 and 57%, respectively. In contrast others have shown a much lower 1-year recurrence rate. Shull reported on the safety and efficacy of the paravaginal repair but this procedure may also vary in success from 67 - 100%. Taken all together however, interpretation of these studies is difficult since the patients included have undergone at least one (in most cases several) vaginal surgical procedures at the same time and some studies even include patients with recurrence together with patients scheduled for primary vaginal surgery. Secondly, there is a need for simple procedures, which can be performed in an outpatient clinic and thirdly, the surgery should be acceptable for the women, i.e. without postoperative pain, short recovery period and no need for further surgical intervention.
In most centers a vaginal surgical repair of an anterior genital prolapse is performed in a standard manner through a midline incision followed by dissection of the vaginal mucosa from the pubocervical fascia. Interrupted sutures approximating the fascia at the midline then repair the cystocele. However, this may not be sufficient in those cases where no fascia is present or the presence of huge defects in the pubocervical fascia. As a consequence the use of mesh have been more popular. Several studies report a reduced recurrence rate following anterior repair using different types of mesh such as biomesh (6,7) or nonabsorbable mesh. The latter has been shown to be associated with vaginal erosion 8 - 2%%, which probably is related to the strong inflammatory response observed after implementation of such mesh. Another complication is shrinkage of the vaginal mucosa and this may be followed by sexual dysfunction or dyspareunia.
Polypropylene mesh appears to induce less inflammatory respons compared to other types. A specific type of mesh is the Avaulta Biosynthetic Mesh, which is a polypropylene mesh coated with collagen. This layer protects against inflammatory response and is slowly resolved.
Since most studies have included patients undergoing several vaginal surgical procedures at the same time, it is difficult to conclude whether or not the use of mesh is superior compared to conventional technique. Furthermore, only sparse information is available regarding sexual function and dyspareunia following vaginal prolapse surgery. Especially there is a lack of information regarding new mesh types.
The purpose of the present study is therefore to test the hypothesis that the Avaulta Biosynthetic Mesh is associated with a lower recurrence rate after two years of follow-up compared to conventional anterior repair. Secondly, the study is planned to evaluate the frequency of sexual dysfunction following vaginal anterior repair, and if there is any difference between the two surgical methods.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00918099
|Contact: Martin Rudnicki, ass email@example.com|
|Roskilde University Hospital||Recruiting|
|Roskilde, Denmark, 4000|
|Contact: Martin Rudnicki, ass professor firstname.lastname@example.org|
|Principal Investigator: Martin Rudnicki|